Enavatuzumab
From Wikipedia, the free encyclopedia
Monoclonal antibody
Pharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | TWEAK receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6334H9792N1700O2000S42 |
| Molar mass | 143104.43 g·mol−1 |
 N Y (what is this?) (verify) | |
Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the TWEAK receptor.[1]
Enavatuzumab was developed by Facet Biotech Corp.[2]
- ↑ Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, et al. (January 2018). "Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors". Molecular Cancer Therapeutics. 17 (1): 215–221. doi:10.1158/1535-7163.MCT-17-0330. PMC 5752572. PMID 29054986.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab" (PDF). American Medical Association.
| Chemokine |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSF |
| ||||||||||||
| Interferon |
| ||||||||||||
| Interleukin |
| ||||||||||||
| TGFβ |
| ||||||||||||
| TNF |
| ||||||||||||
| Others |
| ||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |